Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study
The primary objective of this study is to study the efficacy of a daily dose of 200 mg AZD9056 in patients with active CD affecting ileum and/or colon by assessment of the change in CDAI from baseline...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years and 150 years
AstraZeneca
Update Il y a 5 ans
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib...
Country
France
organs
Ovaire
Specialty
Pharmacologie - Recherche de Transfert
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
Study of MEDI4736 monotherapy and MEDI4736 in combination with Tremelimumab versus Standard of Care Therapy in patients with SCCHN
- To assess the efficacy of MEDI4736 + tremelimumab combination therapy versus SoC in terms of OS
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 24-week, Multi-centre, International, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study with a 78-week Extension Period to Evaluate the Effect of Dapagliflozin in Combination with Metformin on Body Weight in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Alone
To evaluate the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin on total body weight after 24 weeks of oral administration of double...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years and 150 years
AstraZeneca
Update Il y a 4 ans
Étude D081RC00001 : étude de phase 3 randomisée évaluant l’efficacité et la sécurité du durvalumab associé à une chimiothérapie standard à base de platine par rapport au bévacizumab suivi d'un traitement d'entretien par durvalumab associé à du bévacizumab ou par durvalumab, bévacizumab et olaparib chez des patientes ayant un cancer de l'ovaire de stade avancé nouvellement diagnostiqué.
Le cancer de l'ovaire est le 8ème cancer le plus répandu chez les femmes et son diagnostic s'établit généralement à un stade avancé. Dans 90 % des cas, ce sont les cellules épithéliales situées à la s...
Country
France
organs
Ovaire
Specialty
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21
The primary objective of this study is to compare the frequency of events (i.e., presence of DTC in BM, clinical recurrence and/or death) in patients treated with anastrozole-fulvestrant combination a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD Versus Placebo in Patients with Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy
To compare the change from baseline in HbA1c achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metform...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly Controlled on Sulphonylurea Alone Estudio aleatorizado de 24 semanas, doble ciego, de grupos paralelos, controlado con placebo, multicéntrico, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento con Tesaglitazar cuando se añade al tratamiento de pacientes con Diabetes tipo 2 mal controlados con Sulfonilurea en monoterapia. GALLANT 7
To assess the efficacy of tesaglitazar (0.5 and 1 mg) as compared to placebo given as add-on therapy to sulphonylurea for 24 weeks in improving glycaemic control in patients with type 2 diabetes as de...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca HealthCare Foundation (Portugal)
Update Il y a 4 ans
Laboratory tests order communication system optimization: a randomised controlled trial
Background and study aims When inefficiently designed software is combined with a non-evidence based medical practice, the result can be disastrous, leading to patient harm, significant impact to qua...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A study of AZD8931 and anastrozole for hormone receptor positive advanced breast cancer (MINT)
To compare Progression Free Survival (PFS) in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone.
Country
None
organs
None
Specialty
None
unknown
More information
Previous
10
11
12
13
14
15
16
17
18
19
Next